AbbVie (NYSE: ABBV) and REGENXBIO Inc. (Nasdaq: RGNX) today announced updates to the ABBV-RGX-314 clinical program.

The humanised trispecific antibody is undergoing Phase I trials in the US and China in subjects with relapsed or refractory ...

The schizophrenia drug Emraclidine failed to perform in clinical trials but executives say it can still “play a role.” ...

Both parties will also expand research and development efforts. National Taiwan University Hospital (NTUH) and AbbVie ...

AbbVie (ABBV) and Regenxbio (RGNX) announced updates to the ABBV-RGX-314 clinical program. ABBV-RGX-314 in Wet Age-Related Macular ...

The failure of Cerevel's emraclidine in schizophrenia will cost AbbVie an impairment charge of about $3.5 billion, the pharma ...

Gene therapy firm Capsida Biotherapeutics is advancing the first of its AbbVie-partnered neurodegenerative disease therapies ...

ABBV-RGX-314 in Diabetic Retinopathy (DR), Suprachoroidal Delivery AbbVie and REGENXBIO will plan a Phase 3 clinical program ... difficulties inherent in the research and development process ...

AbbVie (NYSE: ABBV) and Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group Ltd (HKEX: 2096) today announced an option to license agreement to develop SIM0500, an investigational new drug ...

are expected in 2026 AbbVie and REGENXBIO will plan the Phase 3 clinical program of investigational ABBV-RGX-314 in diabetic retinopathy (DR) ABBV-RGX-314 in Wet Age-Related Macular Degeneration ...